PRVB News and Press, Provention Bio Inc. From 07/06/21

Gainers: Orbsat (OSAT) +86%.BSQUARE (BSQR) +71%.PFSweb (PFSW) +36%.Advaxis (ADXS) +35%.Powerbridge Technologies (PBTS) +34%.Bridgeline Digital (BLIN) +31%.Sequential Brands Group (SQBG) +24%.GasLog Partners (GLOP) +24%.BioHiTech Global (BHTG) +20%.Data Storage (DTST) +19%.Losers: Pop Culture ...

Ashford Hospitality (AHT) -29% after announces reverse stock split and announces preliminary RevPAR results for Q2 2021Provention Bio (PRVB) -22% after receiving CRL for teplizumab applicationDiDi Global (DIDI) -20% DiDi Global says app takedown in China may hurt...

Provention Bio (PRVB) plummets 21.6% premarket in reaction to the announcement that the FDA has issued a Complete Response Letter ((CRL)) for its Biologics License Application ((BLA)) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.In the CRL,&#...

Provention Bio Receives Complete Response Letter (CRL) to Biologics License Application (BLA) for Teplizumab for the Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals Previously reported pharmacokinetic (PK) drug product comparability considerations remain outstandi...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Gainers: Alector (ALEC) +69%. Lucira Health (LHDX) +9%. Provention Bio (PRVB) +7%.Losers: Iterum Therapeutics (ITRM) -34%. Arrowhead Pharmaceuticals (ARWR) -26%. Alterity Therapeutics (ATHE) -21%. Citius Pharmaceuticals (CTXR) -20%. TRxADE HEALTH (MEDS) -17%. For fu...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s been a big quarter for biotech stocks. Biogen (NASDAQ: BIIB ) had a major breakthrough with the approval of its Alzheimer’s vaccine aducanumab, which is sold under the brand name Aduhelm. It mar...

The Advisory Committee voted 10-7 favoring an approval recommendation for teplizumab. The FDA has given conflicting signals about approval. PDUFA is on July 2. For further details see: Provention Bio: PDUFA Ahead, But Uncertainties Abound

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The stock market got the jobs report it apparently was waiting for, as May's payrolls growth came in short of expectations and led investors ...

Shares of Provention Bio (NASDAQ: PRVB) crashed 28.8% as of the market close on Friday. The huge decline came after a U.S. Food and Drug Administration (FDA) advisory committee voted 10-7 in favor of recommending approval of teplizumab in delaying type 1 diabetes. Investors were...